Sygnature Discovery Ltd acquires leading Canadian CRO
British drug discovery specialist Sygnature Discovery Ltd has taken over Canadian NuChem Sciences Inc., one of North Americas largest discovery CROs
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Enzyme foams morer active and stable
/in News/by Thomas GabrielczykResearchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active.
Bavarian Nordic A/S bags US$120m for smallpox vaccine
/in News/by Thomas GabrielczykBavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.
Neuraxpharm pays US$650m for MS drug commercialisation
/in News/by Thomas GabrielczykTG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
PureTech Health gets US$11.4m to advance LYT-300
/in News/by Thomas GabrielczykLSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
Mithra Pharmaceuticals SA in 17m licencing deal
/in News/by Thomas GabrielczykMithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada.
Bacterial-fungal consortium denitrifies wastewater by 100%
/in News/by Thomas GabrielczykA German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%.
NK cell therapy company NK:IO raises seed money
/in News/by Thomas GabrielczykBritish NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
Alnylam in US$2.8bn biobucks deal with Roche
/in News/by Thomas GabrielczyksiRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive. T
Resistance blocker of immune checkpoint inhibitors gets patented
/in News/by Thomas GabrielczykThe EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.